A Phase 2 interventional study of HRS-7535 in Chronic Weight Management, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The Objective of this trial is to evaluate the long-term safety, tolerability, weight loss efficacy and metabolic benefits of HRS-7535 tablets inobesity.
Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive escalated dose of HRS-7535 or maximum tolerated dose orally
Drug: HRS-7535
Subjects will receive escalated dose of HRS-7535 or maximum tolerated dose orally
Drug: HRS-7535
Subjects will receive escalated dose of HRS-7535 or maximum tolerated dose orally
Drug: HRS-7535
Subjects will receive escalated dose of HRS-7535 or maximum tolerated dose orally
Drug: HRS-7535
HRS-7535
Number of participants with Treatment-emergent Adverse Event(AE)
Time frame: During the 32-week open-label extension treatment period
Percentage change in body weight from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;
Time frame: from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;
Proportion of subjects with ≥5%, ≥10%, and ≥15% weight reduction from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;
Time frame: from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;
Changes in weight from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;
Time frame: from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;
Changes in waist circumference from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;
Time frame: from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;
Changes in body mass index (BMI) from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;
Time frame: from baseline before HRS-7535 tablet treatment to Week 32 of open-label extension treatment;
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Nov 2024 to primary completion in Aug 2025, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Safiglipron
Shandong Suncadia Medicine Co., Ltd. →